Cost-effectiveness of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitor in the treatment of acute ST-segment elevation myocardial infarction

Matthias Schwenkglenks, Toby J Toward, Stephanie Plent, Thomas D Szucs, Daniel J Blackman, Andreas Baumbach

Research output: Contribution to journalArticle (Academic Journal)peer-review

24 Citations (Scopus)

Fingerprint Dive into the research topics of 'Cost-effectiveness of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitor in the treatment of acute ST-segment elevation myocardial infarction'. Together they form a unique fingerprint.

Medicine & Life Sciences